Advertisement

Advertisement
COVID-19
Survivorship

Adult Survivors of Childhood Cancer May Be at Increased Risk of Severe COVID-19 Infection

People who have survived cancer as children may be at a higher risk of developing severe COVID-19 infection—even decades after their cancer diagnosis, according to results published by Louro et al in The Lancet Regional Health – Europe.

 

Leukemia

Can Planned C-Sections Increase the Risk of Childhood ALL?

Children born by planned cesarean section (C-section) may have an increased risk of developing acute lymphoblastic leukemia (ALL) later in life, according to a recent study published by Kampitsi et al in the International Journal of Cancer. Alhough the researchers did find an association, they emphasized that the overall cancer risk in this population remains low.

 

Breast Cancer

BMI and Cardiovascular Disease Associated With Increased Breast Cancer Risk

Weight-associated risk for developing breast cancer after menopause may be higher among women with cardiovascular disease compared with those without cardiovascular disease and women with or without type 2 diabetes, according to the results of two prospective European cohort studies, which were published in Cancer

 


Advertisement
Hepatobiliary Cancer

Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC

The U.S. Food and Drug Administration (FDA) has approved SIR-Spheres Y-90 resin microspheres, manufactured by Sirtex, for the treatment of unresectable hepatocellular carcinoma (HCC). With this approval, these microspheres become the only radioembolization therapy approved for the treatment of both colorectal cancer that has metastasized to the liver and HCC in the United States.

 

Skin Cancer

Intratumoral BO-112 With Pembrolizumab in Anti–PD-1–Resistant Melanoma

In a Spanish-French phase II trial (SPOTLIGHT-203) reported in the Journal of Clinical Oncology, Márquez-Rodas et al investigated the combination of the intratumoral agent BO-112 and pembrolizumab for activity in patients with advanced anti–PD-1–resistant melanoma. BO-112 is a synthetic, double-stranded RNA nanoplexed with polyethylenimine that has shown potential in reversing such resistance in solid tumors.

 

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Gynecologic Cancers

Mailed Self-Collection HPV Tests Improve Cervical Cancer Screening Rates, Study Finds

Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at The University of Texas MD Anderson Cancer Center. In the real-world,...

Advertisement

Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer

The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or long-term quality of life, although the study failed to meet its primary endpoint of overall...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award

W. Kimryn Rathmell, MD, PhD, FASCO W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and...

The Ohio State Appoints Christian Rolfo, MD, PhD, MBA, to Lead Division of Medical Oncology

Christian Rolfo, MD, PhD, MBA Christian Rolfo, MD, PhD, MBA, has been appointed Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James). He will assume this...

Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma

A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Lung Cancer

I Was Expecting to Hear I Have Heart Disease, Not Cancer

In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a heart attack the year before, and I worried that I was at risk for the same fate. It was a complete ...

Advertisement

Surgery vs Ablation in Small Hepatocellular Carcinoma

In two Japanese studies (SURF-RCT and SURF-Cohort) reported in the Journal of Clinical Oncology, Kawaguchi et al compared the outcomes of surgery vs radiofrequency ablation (RFA) in patients with small hepatocellular carcinoma (HCC). Study Details Two multicenter studies were performed, with...

ASCO Post X Feed
Social Media Hub by Everwall